StockNews.AI
ARGX
StockNews.AI
83 days

argenx Announces Results of Annual General Meeting of Shareholders

1. 91.1% shareholder representation at Annual General Meeting. 2. Shareholder approval for annual report and director re-appointment. 3. Remuneration policy adoption failed to achieve required majority. 4. Board authorized to issue shares for up to 10% of outstanding capital. 5. Company is advancing its portfolio in severe autoimmune diseases.

4m saved
Insight
Article

FAQ

Why Neutral?

Shareholder support for key initiatives is positive but remuneration issues raise concerns. Historically, share price can remain stable post-AGM with minor issues.

How important is it?

Results of the AGM are relevant but do not indicate immediate significant changes in operations or financials.

Why Short Term?

Immediate effects from AGM results may influence investor sentiment briefly. Long-term impacts depend on future product success and market expansion.

Related Companies

VRTXABBVBMY
May 28, 2025 16:01 ET  | Source: argenx SE May 28, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held on May 27, 2025. 91.1% of the Company’s share capital was represented at the Annual General Meeting. All items on the agenda received the required majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). This agenda item received a 73.0% majority where a 75% majority was required. As part of the approved resolutions: The Company’s 2024 remuneration report received a 76.7% majority in favor advisory vote;The Company's annual report and annual accounts for the financial year ending December 31, 2024 were approved with a 99.9% majority;Anthony Rosenberg has been re-appointed as non-executive director to the Board of Directors for a term of two years with a 93.6% majority; andThe Board of Directors was authorized to issue shares and grant rights to subscribe for shares in the share capital of the Company for up to 10% of the outstanding share capital at the date of the meeting and for a period of 18 months from the meeting and to limit or exclude statutory pre-emptive rights with a 99.4% majority. The voting result and all documents relating to the shareholders’ meeting will be available on the argenxwebsite at www.argenx.com/investors/shareholder-meetings. About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube. For further information, please contact:   Media: Ben PetokBpetok@argenx.com Investors: Alexandra Roy (US) aroy@argenx.com 

Related News